Skip to main content
. 2016 Jun 7;7(29):45687–45701. doi: 10.18632/oncotarget.9920

Figure 2. miR-26a desensitizes NSCLC cells to Gefitinib.

Figure 2

A. Lung cancer SPCA1 cells were transfected with miR-26a antagomirs, followed by treatment with or without 15 μM Gefitinib, MTT assays were performed at indicated time points. B. SPCA1 cells were transfected with miR-26a antagomirs or control antagomirs, followed by treatment with increasing concentrations of gefitinib (0-40μM) to measure the IC50 values. MTT assays were performed 48 h after Gefitinib treatment. C. Lung cancer PC-9 cells were transfected with miR-26a mimics, followed by treatment with or without 15 μM gefitinib, MTT assays were performed at indicated time points. D. PC-9 cells were transfected with miR-26a mimics or control mimics, followed by treatment with increasing concentrations of gefitinib to measure the IC50 values. MTT assays were performed 48 h after gefitinib treatment. Data are represented as the mean ± SD of three replicates. *P<0.05, ** P<0.01, vs NC group.